Brooks Laboratories informs about outcome of board meeting

10 Aug 2022 Evaluate

With reference to Regulation 30 & Regulation 33 of SEBI (Listing Obligations and Disclosure Requirements), Regulations, 2015, Brooks Laboratories has informed that the Board of Directors at its meeting held today has, approved the Unaudited Standalone and Consolidated Financial Results of the Company for the 1st quarter ended 30 June, 2022. The Audit Committee reviewed the Unaudited Standalone and Consolidated Financial Results at its meeting held earlier today which have been subject to a limited review by the Statutory Auditors. The company has attached a copy of the approved Unaudited Standalone and Consolidated Financial Results for the quarter ended 30.06.2022 along with the Limited Review Report of the Auditors.

The above information is a part of company’s filings submitted to BSE.

Brooks Laboratories Share Price

165.50 3.20 (1.97%)
20-Dec-2024 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1808.50
Dr. Reddys Lab 1342.45
Cipla 1472.45
Lupin 2147.55
Zydus Lifesciences 973.90
View more..
© 2024 The Alchemists Ark Pvt. Ltd. All rights reserved. MoneyWorks4Me ® is a registered trademark of The Alchemists Ark Pvt. Ltd.